STOCK TITAN
  1. Home
  2. News
  3. LIPO

Lipella Pharmaceuticals Inc - LIPO STOCK NEWS

Welcome to our dedicated news page for Lipella Pharmaceuticals (Ticker: LIPO), a resource for investors and traders seeking the latest updates and insights on Lipella Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lipella Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lipella Pharmaceuticals's position in the market.

News
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
Rhea-AI Summary
Lipella Pharmaceuticals, a clinical-stage biotechnology company, has expanded its Scientific Advisory Board to include oncology expertise. The new committee members, Dr. Jason Hafron and Dr. Pradeep Tyagi, bring valuable clinical and translational research experience in cancer treatment, specifically urologic oncology. The company aims to advance its discovery efforts in treating non-muscle invasive bladder cancer (NMIBC) with the help of these experts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
management
-
News
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024
Rhea-AI Summary
Lipella Pharmaceuticals Inc. announces acceptance of abstract for ASCO 2024 meeting, presenting novel treatment strategy for bladder cancer. The abstract focuses on intravesical administration of pembrolizumab to minimize toxicity, highlighting preclinical data efficacy in mice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
News
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis
Rhea-AI Summary
Lipella Pharmaceuticals Inc. (LIPO) receives FDA Type C meeting to discuss Phase-2b trial design for LP-10 in treating hemorrhagic cystitis. The potential treatment targets moderate to severe cases caused by cancer treatments. Dr. Michael Chancellor, Lipella's Chief Medical Officer, expresses eagerness for advancing the program. Lipella successfully completed a Phase-2a trial showing safety and potential efficacy. The upcoming Phase-2b trial aims to enroll 36 subjects in a double-blind, placebo-controlled study focusing on reducing gross hematuria episodes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
News
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline
Rhea-AI Summary
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) receives FDA approval for clinical testing of LP-410 in treating oral Graft-Versus-Host Disease, with trials expected to begin in Q2 2024. This marks a significant milestone for the company in addressing unmet medical needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.57%
Tags
clinical trial
-
News
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference
Rhea-AI Summary
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) announces Chief Medical Officer Dr. Michael Chancellor's presentation at the PropThink Digital Investor Conference on February 23, 2024, discussing hemorrhagic cystitis and the lead candidate LP-10. The presentation will cover bladder cancer, lasting side effects, potential therapies, tacrolimus treatment, and Lipella's Phase 2b clinical trial for HC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished
Rhea-AI Summary
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has been granted two orphan drug designations by the FDA. The company has achieved significant milestones over the past year, including successful clinical program completion for LP-10 and FDA approval for its IND application for a Phase 2a multicenter trial of an oral rinse formulation of LP-310. Lipella has also secured central IRB approval and orphan drug designation for LP-310 for the treatment of oral GVHD with tacrolimus.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.28%
Tags
none
News
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease
Rhea-AI Summary
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has been granted 'Orphan Drug Designation' from the U.S. FDA for its LP-310 drug candidate, aimed at treating oral Graft-versus-Host Disease (GvHD) and other inflammatory diseases of the oral cavity. The FDA's designation provides incentives and potential market exclusivity for the drug.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.13%
Tags
none
-
News
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Lipella Pharmaceuticals Inc. has closed its private placement transaction, raising approximately $2 million. The company plans to use the net proceeds for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.95%
Tags
none
-
News
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Rhea-AI Summary
Lipella Pharmaceuticals has announced a private placement transaction for the purchase and sale of pre-funded warrants and warrants. The gross proceeds are expected to be approximately $2 million, which will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.21%
Tags
none
News
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference
Rhea-AI Summary
Lipella Pharmaceuticals to present at the 2023 virtual Fall Foliage MicroCap Rodeo Conference. CEO highlights positive results from Phase 2a clinical study and FDA approval of Investigational New Drug application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.31%
Tags
conferences
Stock LIPO logo
Lipella Pharmaceuticals Inc

Nasdaq:LIPO

LIPO Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

LIPO Stock Data

4.89M
3.77M
45.56%
5.48%
0.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Pittsburgh